Amgen Stock
Amgen Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- CEO
- Robert A. Bradway
- Employees
- 31,500
- Market cap
- $233.8 B
- IPO
- 17/06/1983
Amgen Inc. is a global pioneer in the Healthcare / Drug Manufacturers - General sector, headquartered in Thousand Oaks, California. The U.S.-based company focuses on the discovery and delivery of innovative therapeutics in oncology, immunology, and cardiovascular disease. Key products in its portfolio include Enbrel…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Amgen stock: price history
1D
-0.4%
1W
+4.2%
1M
+14.9%
6M
+21.7%
YTD
+32.1%
1Y
+46.2%
2Y
+34.5%
5Y
+108.1%
10Y
+165.7%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~54% stronger price swings than usual
Amgen stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Amgen Inc. is a globally operating biotechnology company specialized in the discovery, development, and manufacturing of innovative medicines. Its portfolio covers various therapeutic areas, including oncology, immunology, cardiovascular diseases, as well as bone health and neurosciences. Key products include active ingredients such as Enbrel, Prolia, Repatha, and Otezla. Distribution takes place worldwide through various channels, with primary customers in the healthcare sector, including clinics, hospitals, pharmacies, and specialized medical providers.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Eli Lilly and CompanyDescription
Verastem, Inc.DescriptionAsk the agents about Amgen
Analyst assessment of Amgen
PRICE TARGET LOW
US$230.00
CONSENSUS
US$401.16
MEDIAN
US$410.00
PRICE TARGET HIGH
US$500.00
0
STRONG BUY
22
BUY
16
HOLD
3
SELL
0
STRONG SELL
41
TOTAL · Buy
As of: 13/10/2026
Amgen stock metrics
P/E
26.66
P/B
19.98
EV/EBITDA
15.73
RETURN ON EQUITY
20.3%
NET MARGIN
23.6%
DEBT/EQUITY
4.9
DIVIDEND YIELD
2.3%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.7%
FLOAT SHARES
539,156,080
AVG. DAILY VOLUME (30D)
3,106,502
Insider transactions (SEC)
Khosla Rachna
Khosla Rachna
Khosla Rachna
Busch Matthew C.
ISHRAK OMAR
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.4%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Amgen stock
What does Amgen do?
Amgen Inc. is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.
The CEO is Robert A. Bradway, the company employs around 31,500 people.
The IPO was on 17/06/1983; the stock trades on NASDAQ under the ticker AMGN.
What do analysts say about Amgen stock?
41 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$401.16, ranging from US$230.00 to US$500.00, with a median of US$410.00.
This is an external assessment, not a statement by Market Jury.
When does Amgen report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 54% stronger than usual.
Does Amgen pay a dividend?
Yes. The last dividend was US$2.52 per share, ex-date 21/08/2026, paid on 11/09/2026.
The dividend yield is 2.3% (as of 30/06/2026).
Which stocks are comparable to Amgen?
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Gilead Sciences, Pfizer, Bristol-Myers Squibb Company and Biogen.
How can I get Amgen stock analyzed?
Clicking "Analyze stock" lets five strategies assess Amgen against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.